Related references
Note: Only part of the references are listed.Patterns of progression in patients treated for immuno-oncology antibodies combination
Alice Bernard-Tessier et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma
Geoffrey T. Gibney et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
Lucas Basler et al.
CLINICAL CANCER RESEARCH (2020)
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
Patricia Martin-Romano et al.
CANCER MEDICINE (2020)
Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis
Hyo Jung Park et al.
RADIOLOGY (2020)
Treatment after progression in the era of immunotherapy
Salem Billan et al.
LANCET ONCOLOGY (2020)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Imaging of Cancer Immunotherapy: Current Approaches and Future Directions
Mizuki Nishino et al.
RADIOLOGY (2019)
Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response
Minghao Wu et al.
RADIOLOGY-IMAGING CANCER (2019)
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
Julia A. Beaver et al.
LANCET ONCOLOGY (2018)
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies
Jenny H. Lee et al.
JAMA ONCOLOGY (2018)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials
Georgina V. Long et al.
JAMA ONCOLOGY (2017)
Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2017)
Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2017)
Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review
Paola Queirolo et al.
CANCER TREATMENT REVIEWS (2017)
Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study
L. Cabel et al.
ANNALS OF ONCOLOGY (2017)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
Luisa Carbognin et al.
PLOS ONE (2015)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Immunostimulatory monoclonal antibodies for cancer therapy
Ignacio Melero et al.
NATURE REVIEWS CANCER (2007)
Share Paper
